The historical rank and industry rank for Alar Pharmaceuticals's Net Margin % or its related term are showing as below:
ROCO:6785'
s Net Margin % Range Over the Past 10 Years
Min: -23799.5 Med: -2894.41 Max: 312.36
Current: -2894.41
ROCO:6785's Net Margin % is ranked worse than 97.92% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs ROCO:6785: -2894.41
Alar Pharmaceuticals (ROCO:6785) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Alar Pharmaceuticals Net Margin % Related Terms
Alar Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a Net Margin % of -1,696.40% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Alar Pharmaceuticals and its competitors. According to the industry distribution chart, Alar Pharmaceuticals ranks #942 out of 962 companies in the Drug Manufacturers industry, placing it in the top 97.9%.
Is Alar Pharmaceuticals' Net Margin % too high?
Alar Pharmaceuticals' current Net Margin % is -1,696.40%. Based on the distribution chart, Alar Pharmaceuticals ranks #942 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #942 out of 962 companies for Net Margin %. This places Alar Pharmaceuticals in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Net Margin % is -1,696.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current Net Margin % is -1,696.40%. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Net Margin % is -1,696.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
Net Margin %: -1,696.40%
GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score
Get the complete analysis for ROCO:6785
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
